Denali Therapeutics Inc. (DNLI) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Denali Therapeutics Inc. is a biopharmaceutical company focused on neurodegenerative and lysosomal storage diseases. The quarter marks a pivotal transition to commercial operations following the U.S. FDA accelerated approval of AVLAYAHTM (tividenofusp alfa-eknm) in March 2026 for the treatment of Hunter syndrome (MPS II). Commercial distribution commenced in April 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3.6 million | $0 | $3.6 million | $0 |
| Net Loss | $(127.6) million | $(124.1) million | $(256.0) million | $(257.1) million |
| Operating Expenses | $134.1 million | $135.0 million | $271.5 million | $280.5 million |
| R&D Expenses | $97.0 million | $102.7 million | $200.9 million | $218.9 million |
| SG&A Expenses | $36.3 million | $32.3 million | $69.8 million | $61.6 million |
| Cash & Marketable Securities | $940.0 million (as of June 30, 2026) | |||
| Accumulated Deficit | $2.31 billion (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $3.6 million in product revenue for the first time, driven by AVLAYAH sales. This contrasts with zero revenue in the prior year periods.
- Cost of Goods Sold (COGS): COGS of $0.1 million was recognized for the first time. The low per-unit cost reflects the utilization of inventory previously expensed as R&D prior to FDA approval.
- Intangible Asset Amortization: A new expense line item of $0.75 million was recorded, related to the capitalization of a $36.0 million milestone payment for AVLAYAH technology rights.
- Financing Activity: The company received $200.0 million in gross proceeds from a synthetic royalty funding agreement with Royalty Pharma, recorded as a liability. This introduced $5.9 million in non-cash interest expense.
- Collaboration Updates:
- Biogen: The Phase 2b LUMA study for DNL151 in idiopathic Parkinson's disease failed to meet endpoints; development in this indication was discontinued.
- Takeda: Terminated the PTV:PGRN collaboration; Denali regained full rights to the DNL593 program.
Outlook, Risks, and Unusual Items
- Subsequent Event (PRV Sale): In July 2026 (post-period end), Denali sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195.0 million. This transaction is not reflected in the Q2 financial statements but significantly impacts liquidity.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($940.0 million) are sufficient to fund operations for at least 12 months. However, the company expects to continue incurring significant losses as it scales commercialization and R&D.
- Risks: Continued approval of AVLAYAH is contingent on confirmatory clinical benefit in the Phase 2/3 COMPASS trial. The company faces risks related to market acceptance, reimbursement, and the success of its pipeline (including DNL151 in LRRK2 carriers and DNL593).
- Debt/Liability: The Royalty Pharma agreement creates a liability with an effective interest rate of approximately 12%, capped at 3.0x total funding received.
Investor Verification Checklist
- PRV Proceeds: Verify the receipt and accounting treatment of the $195.0 million PRV sale proceeds in the Q3 2026 filing.
- AVLAYAH Commercialization: Monitor patient enrollment and sales velocity in the COMPASS trial and commercial channels to assess revenue sustainability.
- R&D Pipeline: Track progress of the DNL151 BEACON study (LRRK2 variant carriers) and DNL593 (FTD-GRN) following the termination of partner collaborations.
- Capital Expenditures: Review the utilization of the Salt Lake City manufacturing facility and associated costs.
- Regulatory Milestones: Watch for EMA approval of AVLAYAH, which would trigger an additional $75.0 million funding tranche from Royalty Pharma.